A Bispecific Antibody Targeting RBD and S2 Potently Neutralizes SARS-CoV-2 Omicron and Other Variants of Concern
Mengqi Yuan, Xiangyu Chen, Yanzhi Zhu, Xiaoqing Dong, Yan Liu, Zhaohui Qian, Lilin Ye, Pinghuang Liu
Abstract
The new, highly contagious SARS-CoV-2 Omicron variant caused substantial breakthrough infections and has become the dominant strain in countries across the world. Omicron variants usually bear high mutations in the spike protein and exhibit considerable escape of most potent neutralization monoclonal antibodies and reduced efficacy of current COVID-19 vaccines.
Topics & Concepts
AntibodyNeutralizationEpitopeMonoclonal antibodyVirologySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)BiologyIC50Neutralizing antibodyCoronavirus disease 2019 (COVID-19)VirusGeneticsMedicineCell cultureDiseasePathologyInfectious disease (medical specialty)SARS-CoV-2 and COVID-19 ResearchSARS-CoV-2 detection and testingRespiratory viral infections research